IPP Bureau
Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets
By IPP Bureau - March 28, 2026
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Shreehas Tambe appointed CEO & Managing Director of Biocon
By IPP Bureau - March 28, 2026
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Novartis acquires Excellergy to bolster allergy portfolio
By IPP Bureau - March 28, 2026
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
By IPP Bureau - March 28, 2026
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Eli Lilly drug shows 4-year relief for eczema patients, study finds
By IPP Bureau - March 28, 2026
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials
By IPP Bureau - March 28, 2026
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal
By IPP Bureau - March 28, 2026
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
Lonza launches Singapore Media Development Lab to cut biomanufacturing risk
By IPP Bureau - March 27, 2026
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
MGM Healthcare builds world’s largest intestinal transplant program in 3 years
By IPP Bureau - March 27, 2026
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
HDFC Bank, Smile Foundation launch 8 mobile medical units to serve 4 lakh in remote north India
By IPP Bureau - March 27, 2026
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
India gets first real-time GLP-1 therapy monitoring platform
By IPP Bureau - March 27, 2026
As Tracky launches integrated health solution
CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG
By IPP Bureau - March 27, 2026
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
Cambrex advances $120M US API expansion with Charles City Engineering milestone
By IPP Bureau - March 27, 2026
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Northamptonshire NHS Trust ditches disposable cups in bold sustainability move
By IPP Bureau - March 27, 2026
The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs
Ibex Medical Analytics joins forces with HNL Lab Medicine to supercharge AI diagnostics
By IPP Bureau - March 26, 2026
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
